A phase I study of regulatory T cell depletion with denileukin diftitox followed by active immunotherapy with autologous dendritic cells infected with CEA-6D expressing fowlpox-tricom [cancer vaccine] in patients with advanced or metastatic malignancies expressing CEA [carcinoembryonic antigen]

Trial Profile

A phase I study of regulatory T cell depletion with denileukin diftitox followed by active immunotherapy with autologous dendritic cells infected with CEA-6D expressing fowlpox-tricom [cancer vaccine] in patients with advanced or metastatic malignancies expressing CEA [carcinoembryonic antigen]

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2012

At a glance

  • Drugs Cancer vaccine (Primary) ; Denileukin diftitox (Primary)
  • Indications Cancer metastases
  • Focus Adverse reactions
  • Most Recent Events

    • 01 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 06 Apr 2008 Status changed from recruiting to in progress, as reported by ClinicalTrials.gov.
    • 16 Jan 2008 The expected completion date for this trial is now 1 Mar 2006.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top